← All trials
NCT06230354
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2024
- Primary completion
- Oct 31, 2025
- Completion date
- Oct 31, 2025
- First posted
- Jan 30, 2024
- Last posted
- Apr 18, 2024
- Enrollment
- 66
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Imperial College LondonLead sponsor
- Imperial College LondonOfficial
- AstraZenecaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.